Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Healthcare Biotechnology

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc

Bullboard Posts

Comment by RPINVESTOR1on Jan 08, 2020 6:24pm

92 Views

Post# 30532499

RE:RE:RE:RE:RE:Gratitude & Promise

MetzGer:-

They don't need to publish the data. However, when interested parties call the medical people who conducted the trial and they tell them that they should speak to Shiseido, the Company should give them an answer if the trials were not successful. It is only common courtesy and Shiseido can then let these people tell the World about the failed trial. This would help Shiseido because they would not have to make an announcement about the failed trial.

To my knowledge Shiseido has not answered directly any questions about the Phase 2 Trial.
Their silence is highly significant.

Bullboard Posts

Critical materials crisis: Diversifying away from China’s monopoly